Reed Jobs, founder of the oncology-focused venture firm Yosemite, recently confirmed the first close of the company’s second fund, targeting $350 million. Three years after launching the firm, Jobs has expanded the internal team to 17 and grown the portfolio to nearly 25 companies. Yosemite operates on a hybrid model that pairs no-strings-attached philanthropic grants with traditional venture capital to convert early academic research into clinical-stage biotech ventures. Approximately one-third of the new fund will finance internally developed companies, while the remainder will be deployed into external partnerships, with an additional 2.5 percent of assets under management and annual management fees allocated to foundational research grants. The firm’s strategy aligns with a rapidly maturing biotech environment. Following a post-pandemic industry slowdown, record pharmaceutical cash reserves and a synchronized patent cliff have sparked an aggressive acquisition cycle. Notable market movements include Eli Lilly’s $7 billion purchase of Kelonia and breakthrough KRAS-targeting therapies that have doubled survival rates in pancreatic cancer. Yosemite has positioned itself at the forefront of this cycle by pioneering epigenetic gene editing and induced proximity therapeutics. Key portfolio highlights include Azalea, which emerged from Jennifer Doudna’s laboratory, Tune Therapeutics, which applies epigenetic silencing to hepatitis B, and Histosonics, a medical device startup utilizing histotripsy to ablate liver and pancreatic tumors. Artificial intelligence has become a core component of Yosemite’s investment and operational framework. Jobs emphasizes that AI accelerates reproducible computational workflows and enables the targeting of historically undruggable genomic regions. Historically constrained to roughly 15 percent of the genome, drug discovery now extends to complex protein interactions and cryptic binding sites. The firm is advancing three distinct strategies against p53, the most frequently suppressed tumor suppressor gene across human cancers. Beyond target identification, AI is being integrated into clinical trial design to generate synthetic control arms, potentially halving patient recruitment requirements and significantly reducing the average $260 million cost of Phase III oncology studies. Despite intermittent political pressure, federal support for biomedical research remains structurally secure. Jobs noted bipartisan congressional rejection of proposed National Institutes of Health budget reductions and advocated for sustained funding increases to maintain innovation velocity. He stressed that Yosemite’s sourcing strategy remains strictly merit-based, evaluating proposals based on scientific rigor rather than founder credentials. The firm also advises portfolio executives to anticipate shifting corporate development priorities, secure strategic pharma partnerships carefully, and maintain disciplined narrative execution alongside technical milestones. Looking beyond immediate oncology applications, Jobs expressed skepticism toward generalized longevity ventures, arguing that aging is a multifaceted biological process that demands personalized optimization rather than standardized interventions. Reflecting on Yosemite’s evolution, Jobs noted that the convergence of AI, expanded therapeutic target accessibility, and renewed pharmaceutical capital has accelerated the firm’s progress well beyond initial forecasts, positioning early-stage biotech to resolve decades-long scientific bottlenecks and deliver clinically actionable cancer therapies.